Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 2/20 | 0.36 |
| ▸ | ALB | P02768 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1890331 | 0.86 | EPAS1 (0.38) | CYP11B1CYP11B2EPAS1 | |
| SCHEMBL29639654 | 0.86 | EPAS1 (0.38) | CYP11B1CYP11B2EPAS1 | |
| SCHEMBL12326823 | 0.84 | ALDH1A1 (0.38) | VCAM1CYP11B1CYP11B2TTRALB | |
| SCHEMBL29374743 | 0.84 | TTR (0.39) | VCAM1CYP11B1CYP11B2TTRALB | |
| SCHEMBL29557004 | 0.84 | GRM5 (0.34) | VCAM1CYP11B1CYP11B2EPAS1 | |
| SCHEMBL23464281 | 0.84 | GRM5 (0.34) | VCAM1CYP11B1CYP11B2EPAS1 | |
| SCHEMBL1195245 | 0.84 | TTR (0.39) | VCAM1CYP11B1CYP11B2TTRALB | |
| SCHEMBL22032973 | 0.84 | EGLN2 (0.33) | VCAM1CYP11B1CYP11B2TTRALB | |
| SCHEMBL23464277 | 0.80 | CYP11B1 (0.32) | CYP11B1CYP11B2TTRALBEPAS1 | |
| SCHEMBL3628529 | 0.80 | EPAS1 (0.41) | EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947709-B2 | Inhibit HIV-1 RT; 3-[6-Bromo-2-fluoro-3-(2-oxo-2,3-dihydro-benzoimidazol-1-ylmethyl)-phenoxy]-5-chloro-benzonitrile for example; AIDS or AIDS-related Complex (ARC) | ROCHE PALO ALTO LLC (US) | 2011-05-24 | — | — | US | disclosed |
| EP-2170836-A1 | UREA AND CARBAMATE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-04-07 | — | — | EP | disclosed |
| US-20090012034-A1 | Non-Nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2009-01-08 | — | — | US | disclosed |
| WO-2009000663-A1 | UREA AND CARBAMATE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012034-A1 | Non-Nucleoside reverse transcriptase inhibitors | REV1, POLR1A, XDH | VCAM1 2073/4885CYP11B1 582/4885CYP11B2 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.